Diligence memo · auto-generated · as of July 2, 2026
Correlia Biosystems, Inc.
Correlia Biosystems, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Correlia Biosystems, Inc. operates in Biotechnology, based in BERKELEY, CA, USA. Next-gen blood testing to provide 1000x more data to pharma companies
Sub-sector tags: Hardware, Lab-on-a-chip, Microfluidics, medical-devices, pharma.
Capital & rounds (filed)filed
Correlia Biosystems, Inc. has raised $11M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.6M on 2020-10-02.
Most recent recorded round closed around 2023-05-01.
Valuation (modeled)modeled
Provath models Correlia Biosystems, Inc. at approximately $12M (range $1.4M–$33M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.26× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 31 months.
Last raise 3.2 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 7.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 58% of Biotechnology peers (4293 compared).
Modeled value ranks above 20% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.